{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:06:54Z","timestamp":1793740014423,"version":"4.6.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.idnow.2026.105268","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T15:24:30Z","timestamp":1775316270000},"page":"105268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of dalbavancin as suppressive therapy in chronic implant-associated infections"],"prefix":"10.1016","volume":"56","author":[{"given":"Tomaso","family":"Beringheli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Dupieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Goutelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiphaine","family":"Roussel-Gaillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1328-6576","authenticated-orcid":false,"given":"Carole","family":"Dhelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Rascle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Doudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Javaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Triffault-Fillit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Valour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idnow.2026.105268_b0005","first-page":"1222","article-title":"The current and future off-label uses of dalbavancin: a narrative review","volume":"27","author":"De Vito","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.idnow.2026.105268_b0010","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.diagmicrobio.2012.11.024","article-title":"Update of dalbavancin spectrum and potency in the USA: report from the SENTRY Antimicrobial Surveillance Program (2011)","volume":"75","author":"Jones","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.idnow.2026.105268_b0015","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1128\/AAC.04550-14","article-title":"Extended-duration dosing and distribution of dalbavancin into bone and articular tissue","volume":"59","author":"Dunne","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2026.105268_b0020","article-title":"Population pharmacokinetics of dalbavancin and dosing consideration for optimal treatment of adult patients with staphylococcal osteoarticular infections","volume":"65: e02260 \u201320","author":"Cojutti","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2026.105268_b0025","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.749685","article-title":"Biofilm-Related Infections in Gram-positive Bacteria and the potential Role of the Long-Acting Agent Dalbavancin","volume":"12","author":"Oliva","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.idnow.2026.105268_b0030","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/jac\/dkv357","article-title":"Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis","volume":"71","author":"Barnea","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2026.105268_b0035","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1128\/AAC.48.3.1061-1064.2004","article-title":"Activities of dalbavancin in vitro and in a rabbit model of experimental endocarditis due to Staphylococcus aureus with or without reduced susceptibility to vancomycin and teicoplanin","volume":"48","author":"Lefort","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2026.105268_b0040","article-title":"Dalbavancin for the Treatment of Osteomyelitis in Adult patients: a Randomized Clinical Trial of Efficacy and Safety. Open Forum","volume":"6","author":"Rappo","year":"2019","journal-title":"Infect Dis"},{"key":"10.1016\/j.idnow.2026.105268_b0045","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/cid\/ciae302","article-title":"The use of long-term Antibiotics for suppression of Bacterial Infections","volume":"79","author":"Horne","year":"2024","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.idnow.2026.105268_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1185602","article-title":"Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety","volume":"14","author":"Ruiz-Sancho","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.idnow.2026.105268_b0055","article-title":"Multiple-Dose Dalbavancin Regimens as the Predominant Treatment of Deep-Seated or Endovascular Infections: a Scoping Review. Open Forum","volume":"8","author":"Cooper","year":"2021","journal-title":"Infect Dis"},{"key":"10.1016\/j.idnow.2026.105268_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106773","article-title":"A descriptive case series of the relationship between maintenance of conservative PK\/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections","volume":"61","author":"Gatti","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.idnow.2026.105268_b0065","unstructured":"Jamovi [Internet]. n.d. Jamovi [cited April 3, 2026]. Available from: https:\/\/www.jamovi.org\/."},{"key":"10.1016\/j.idnow.2026.105268_b0070","article-title":"The EBJIS definition of periprosthetic joint infection","volume":"103-B:18\u201325","author":"McNally","year":"2021","journal-title":"Bone Jt J"},{"key":"10.1016\/j.idnow.2026.105268_b0075","doi-asserted-by":"crossref","first-page":"7833","DOI":"10.1128\/AAC.01717-15","article-title":"Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target","volume":"59","author":"Lepak","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.idnow.2026.105268_b0080","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s10096-024-04849-0","article-title":"Dalbavancin as suppressive therapy for implant-related infections: a case series with therapeutic drug monitoring and review of the literature","volume":"43","author":"Lafon-Desmurs","year":"2024","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"10.1016\/j.idnow.2026.105268_b0085","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1007\/s15010-025-02619-4","article-title":"Practice guidelines for outpatient parenteral antimicrobial therapy (OPAT) in Germany","volume":"53","author":"Tometten","year":"2025","journal-title":"Infection"},{"key":"10.1016\/j.idnow.2026.105268_b0090","article-title":"Experience with dalbavancin for long-term antimicrobial suppression of left ventricular assist device infections","volume":"25","author":"Mansoor","year":"2023","journal-title":"Transpl Infect Dis Off J Transplant Soc"},{"key":"10.1016\/j.idnow.2026.105268_b0095","first-page":"1639","article-title":"Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections","volume":"12","author":"Gallerani","year":"2023","journal-title":"Antibiot Basel Switz"},{"key":"10.1016\/j.idnow.2026.105268_b0100","first-page":"910.e1","article-title":"Dalbavancin exposure invitro selects for dalbavancin-non-susceptible and vancomycin-intermediate strains of methicillin-resistant Staphylococcus aureus","volume":"27","author":"Werth","year":"2021","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idnow.2026.105268_b0105","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlae163","article-title":"Dalbavancin-resistant Staphylococcus epidermidis in vivo selection following a prosthetic joint infection: phenotypic and genomic characterization","volume":"6","author":"Ruffier d\u2019Epenoux","year":"2024","journal-title":"JAC-Antimicrob Resist"},{"key":"10.1016\/j.idnow.2026.105268_b0110","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41426-018-0205-z","article-title":"Emergence of a dalbavancin induced glycopeptide\/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis","volume":"7","author":"Kussmann","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.idnow.2026.105268_b0115","first-page":"429.e1","article-title":"Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen","volume":"24","author":"Werth","year":"2018","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"10.1016\/j.idnow.2026.105268_b0120","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s40261-021-01028-3","article-title":"Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment costs in Different Gram-positive Bacterial Infections","volume":"41","author":"Poliseno","year":"2021","journal-title":"Clin Drug Invest"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991926000254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991926000254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:42:06Z","timestamp":1780339326000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991926000254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2666991926000254"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2026.105268","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of dalbavancin as suppressive therapy in chronic implant-associated infections","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2026.105268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"105268"}}